OrthoTrophix Homepage

Latest News

May 13, 2019
TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee

October 23, 2018
OrthoTrophix Presents Knee Cartilage Structure Modification Data of TPX-100 at American College of Rheumatology Annual Meeting

October 11, 2018
OrthoTrophix Will Present Clinical Outcome of a TPX-100 Study Including Knee Cartilage Structure Modification Data at Annual Meeting of American College of Rheumatology 2018


OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage and teeth. The primary focus of OrthoTrophix is regeneration and repair of cartilage in the knee and other joints. The company’s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other parameters of the knees in knee osteoarthritis subjects in a Phase 2 clinical study. In addition, the significant improvement of knee function was linked to a significant improvement in knee cartilage thickness and volume. Prior to initiation of clinical studies, TPX-100 had demonstrated ability to repair articular (hyaline) cartilage in experimental defects in the knee joints of ambulatory large animal models.